The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

July 16, 2022

Conditions
Congenital Heart Disease in ChildrenCardiopulmonary Bypass
Interventions
DRUG

Placebo

50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.

DRUG

Dexmedetomidine Hcl 100 Mcg/mL Inj

1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.

DRUG

Dexmedetomidine Hcl 100 Mcg/mL Inj

0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.

Trial Locations (1)

11420

National Cardiovascular Center Harapan Kita Hospital Indonesia, Jakarta

All Listed Sponsors
lead

National Cardiovascular Center Harapan Kita Hospital Indonesia

OTHER

NCT05300802 - The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study | Biotech Hunter | Biotech Hunter